Symeres is the leading mid-sized European Contract Research Organization for your drug-discovery and development challenges. With over 500 scientists, we offer best-in-class solutions for drug discovery and drug development, from small to medium-sized molecule hits. Our services span across early stage hit finding all the way to the delivery of your early clinical drug substance API. We blend vast scientific knowledge with inventiveness to make great leaps on your behalf. We Make Molecules Matter.
Location: Netherlands, Gelderland, Nijmegen
Employees: 201-500
Founded date: 1987
Investors 2
| Date | Name | Website |
| - | Gilde Heal... | gildehealt... |
| 22.05.2025 | Keensight ... | keensightc... |
Mentions in press and media 3
| Date | Title | Description |
| 10.09.2025 | Symeres acquires DGr Pharma to enhance regulatory expertise and broaden its biopharma capabilities | - |
| 27.10.2022 | Netherlands-based Symeres acquires Exemplify Biopharma | Nijmegen, Netherlands-based global drug discovery company, Symeres acquired Exemplify Biopharma. The company announced the acquisition on October 25, 2022. However, the company did not disclose the amount of the purchase. Keensight Capital ... |
| 26.10.2022 | Symeres Acquires Exemplify BioPharma | Symeres, a Nijmegen, Netherlands-based global drug discovery company, acquired Exemplify BioPharma, a Cranbury, NJ-based provider of integrated drug development services. The amount of the deal was not disclosed. With the acquisition, Symer... |